Journal article
Development of a novel strategy to target CD39 antithrombotic activity to the endothelial-platelet microenvironment in kidney ischemia–reperfusion injury
M Sashindranath, KM Dwyer, S Dezfouli, C Selan, S Crikis, B Lu, Y Yuan, MJ Hickey, K Peter, SC Robson, PJ Cowan, HH Nandurkar
Purinergic Signalling | SPRINGER | Published : 2017
Abstract
Kidney ischemia–reperfusion injury (IRI) is common during transplantation. IRI is characterised by inflammation and thrombosis and associated with acute and chronic graft dysfunction. P-selectin and its ligand PSGL-1 are cell adhesion molecules that control leukocyte-endothelial and leukocyte-platelet interactions under inflammatory conditions. CD39 is the dominant vascular nucleotidase that facilitates adenosine generation via extracellular ATP/ADP-phosphohydrolysis. Adenosine signalling is protective in renal IRI, but CD39 catalytic activity is lost with exposure to oxidant stress. We designed a P-selectin targeted CD39 molecule (rsol.CD39-PSGL-1) consisting of recombinant soluble CD39 tha..
View full abstractRelated Projects (1)
Grants
Awarded by National Institutes of Health
Funding Acknowledgements
This work was supported by grants awarded to HH Nandurkar from the NHMRC (344801) and NIH (1 R01 HL078651) and to SC Robson from the NIH (5 R01 HL094400).